This week in Pediatrics
Nov 16, 2026
Attention-Deficit/Hyperactivity Disorder Accommodations, Behavior Therapy, and Stimulant Medication: A Randomized Clinical Trial.
In a crossover trial of school-age children with ADHD, methylphenidate and behaviour therapy improved classroom behaviour and work, while extended time, breaks and similar accommodations showed no benefit.
JAMA Pediatrics · 2026 · PubMed
This week’s highlights
Read the weekly briefing
This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.
This week: empirical tuberculosis treatment fails to save infants with HIV pneumonia, a phone-based parenting programme cuts sexual violence against adolescent girls, and classroom accommodations for ADHD show no measurable benefit in a large randomised trial.
Welcome to This Week in Pediatrics. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.
The Lancet published EMPIRICAL, led by Domínguez-Rodríguez, a multicentre, open-label, factorial randomised trial in 19 hospitals across Côte d'Ivoire, Malawi, Mozambique, Uganda, Zambia and Zimbabwe [1]. It enrolled 558 infants aged one to twelve months with severe HIV-associated pneumonia and no current tuberculosis diagnosis. On top of standard care for bacterial and Pneumocystis pneumonia, half of the infants received six months of four-drug tuberculosis treatment from the start, while the other half followed the recommended strategy of treating only when microbiology or clinical judgement pointed to tuberculosis. At twelve months, 48 percent of infants in the empirical group had died, against 43 percent in the guided group, a difference that was not statistically significant. Mortality at fifteen days also did not differ, and serious adverse events were similar, with no treatment-related deaths. The key limitation is contamination: 46 percent of infants in the guided arm started tuberculosis treatment anyway, at a median of four days, which blurs the contrast between strategies. The authors set this result against the trial's valganciclovir comparison, whose figures this abstract does not report. The trial adds randomised evidence that empirical tuberculosis treatment did not improve survival, and it documents mortality close to half at one year in this population.
Also in The Lancet, and also from sub-Saharan Africa, Cluver and colleagues report a cluster-randomised trial of ParentApp in 80 sub-wards of Tanzania [2]. The trial enrolled 2,396 caregivers and their adolescents aged ten to seventeen. Families in intervention clusters received a low-cost Android phone with an offline twelve-module parenting app, one in-person orientation and WhatsApp group support, at a delivery cost of about six dollars per family at scale. Control clusters received a water and sanitation app. Retention was close to ninety percent at eighteen months. Among adolescent girls, past-month sexual violence victimisation was about 57 percent lower in ParentApp clusters, with no effect among boys. Past-month physical abuse, verbal abuse and neglect were modestly lower by both adolescent and caregiver report, and exposure to high-risk situations for sexual violence fell for girls and boys. No adverse events were reported. The main limitation is that participants could not be masked and outcomes were self-reported, which leaves room for reporting bias. The trial adds a rare randomised, scalable prevention result against sexual violence, with a benefit confined to girls.
JAMA Pediatrics published a crossover randomised trial from Fabiano and colleagues that tested common ADHD supports head to head [3]. Children with ADHD in kindergarten through sixth grade attended summer treatment programme classrooms, and 255 children started the intervention, with 235 completing it. Academic accommodations, namely extended time, frequent breaks, a low-distraction workspace and a standing desk, were randomised daily. Methylphenidate at 0.3 milligrams per kilogram alternated weekly with placebo, and an enhanced behavioural classroom alternated every two weeks with a general classroom. Compared with placebo, medication raised seatwork productivity by about a fifth and lifted quiz scores by roughly four points. Classroom rule violations fell by 37 percent with medication and by 61 percent with behaviour therapy. No accommodation improved behaviour or academic outcomes, alone or combined, and no interactions were significant. The most important limitation is setting: these were structured summer classrooms with short exposure periods, and effects in ordinary school years over months were not tested. The trial adds within-child randomised evidence that questions the emphasis on academic accommodations, while supporting behavioural and stimulant treatment, as the authors conclude.
Now, four in brief.
In PLOS Medicine, Juma and colleagues report the antimicrobial resistance sub-study of LAKANA, the cluster-randomised trial of mass azithromycin for infants in Mali that found no mortality benefit [4]. Across 59 villages and about five thousand nasopharyngeal and rectal samples, twice-yearly azithromycin for two years did not increase macrolide resistance in pneumococcus or E. coli, in treated children or in untreated older contacts, and it met the noninferiority margin. Quarterly dosing could not exclude a modest dose-dependent rise, with pneumococcal macrolide resistance around 17 percent at three years against about 13 percent with placebo. The authors note the study may have been too small to detect a small increase.
Antibiotic exposure is also the subject of a ten-year population-based cohort from Oulu in Finland, by Pesonen and colleagues in Acta Paediatrica [5]. Among 2,444 neonates born after 32 weeks and admitted early to intensive care, mostly for respiratory distress, about two thirds of infants received early antibiotics, while true early onset sepsis occurred in only 17 infants, under one percent. The authors argue that mild respiratory symptoms likely did not justify antibiotics. This is a retrospective, single-region record review, and it cannot identify which infants could safely have gone untreated.
In Pediatrics, Tijssen and colleagues present a systematic review and meta-analysis of weight estimation and dose calculation in resuscitation [6]. Of 250 included studies, only nine enrolled children who actually needed resuscitation. The PAWPER tape, a length-based tape with body habitus correction, outperformed the Broselow tape for weight accuracy, dose accuracy and time to drug administration, with roughly two and a half times the odds of an estimate within ten percent. Age-based formulas were consistently inaccurate, with fewer than half of estimates within ten percent. There were no patient outcome data, and children beyond tape length or with skeletal deformities were often excluded.
Also in Acta Paediatrica, Üdürgücü and colleagues describe 225 children with septic shock needing vasoactive drugs across 16 paediatric intensive care units [7]. Epinephrine was the first-line drug in 70 percent of children, most children needed more than one agent, and corticosteroids were started at a median vasoactive inotrope score of 60, close to a threshold the authors link with higher mortality. Overall mortality was 59 percent. The study is descriptive, with no comparison between agents, so it cannot say which drug or sequence is better.
Three quick signals.
In the European Journal of Pediatrics, Mauritz and colleagues update German recommendations for inpatient lower respiratory tract infections in children with severe neurological impairment [8]. They favour an aminopenicillin with a beta-lactamase inhibitor for community-acquired infection, reserve piperacillin-tazobactam for selected high-risk patients, and add guidance on resistant organism colonisation and discharge. The basis is expert consensus.
In the Journal of Pediatrics, Fine and colleagues followed 124 children with Lyme arthritis seen in a paediatric emergency department [9]. About fifteen percent of children received more than four weeks of antibiotics, and six children, about five percent, developed post-antibiotic Lyme arthritis needing an immunomodulator or joint steroid injection. The sample is small and the report is brief.
In JAMA Pediatrics, Kuper and colleagues surveyed 376 people who began gender-affirming hormone therapy as youth at one clinic [10]. Nearly all respondents, about 97 percent, called it the right decision, under three percent reported regret and about two percent perceived harm. Regret was higher among those no longer on therapy and those identifying as nonbinary. The data are self-reported from a single clinic.
Stepping back across this week's papers, the strongest designs mostly delivered null or narrow answers to questions that practice had already settled by habit, while the observational work describes heavy antibiotic and vasoactive use without the comparisons needed to define safer thresholds. The resuscitation evidence rests on measurement accuracy with no patient outcomes behind it, and several self-reported or single-centre datasets carry the selection limits that come with those sources.
If you only have time for one paper this week, make it the ADHD accommodations trial [3]. It brings randomised evidence to one of the most widely used and least tested supports in school-age ADHD, and it reopens the question of how much weight accommodations deserve beside behavioural and stimulant treatment.
That's your roundup for This Week in Pediatrics. The full transcript and references are available on the episode page. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.
This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.
Get Pediatrics every week
By email, Spotify, Apple or any podcast app.
Spot something worth flagging?